Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
The BABY HUG Treatment Study was designed to see if treatment with the drug hydroxyurea (also
called HU) in children with sickle cell disease could prevent organ damage, especially in the
spleen and kidneys. There was also a chance that treatment could prevent painful crises, lung
disease, stroke, and blood infection.